Explore the forefront of regenerative aesthetics with our advanced exosome therapies. These cutting-edge treatments harness the power of cellular messengers to support healing, enhance skin quality, and promote a naturally radiant appearance from the inside out.
ExoGlow™ Facial (Face)
Topical exosomes microneedled into the epidermis to improve tone, texture, and radiance; often paired with RF microneedling.
ExoGlow™ Face + Neck / Face + Neck + Décolleté
Same protocol extended to neck/chest for uniform skin-quality improvement.
ExoRecover™ Post-Laser Boost
Exosome application immediately after fractional laser/RF sessions to support healing, reduce downtime appearance, and enhance glow.
ExoEyes™ Under-Eye Renewal
Targeted under-eye skin-quality support (crepiness, fine lines); typically done in a series.
ExoScalp™ Density Protocol
Scalp microinjections + microneedling aimed at supporting hair density/thickness; performed in cycles (e.g., 3–6 sessions).
ExoScar™ Remodel (Acne/Texture)
Focal treatment for atrophic acne scarring or texture irregularities; usually combined with RF microneedling or subcision plans.
ExoNeck™ & Décolleté Renewal
Skin-quality upgrade for tech-neck lines and chest photodamage; often bundled with Face treatments.
ExoHands™ Rejuvenation
Improves dorsal hand skin quality (texture/crepiness) and complements volumizing fillers when indicated.
ExoBody™ Texture (Abdomen/Knees/Arms)
Larger-area skin refinement for laxity or rough texture; pairs well with RF tightening or fractional devices.
ExoStretch™ Mark Care
Focused series to soften the look of stretch marks, often combined with fractional RF/laser.
Maintenance
Optional single-session refreshers at 3–6 months.
Exosome products used in aesthetics are not FDA-approved to treat diseases; protocols are cosmetic/investigational. We use clinician oversight, medical intake, and informed consent; avoid claims of cure/regrowth—say “supports healing/skin quality/density; individual results vary.” Typical exclusions: pregnancy/breastfeeding, active infections, active cancers, recent isotretretinoin, uncontrolled autoimmune conditions (per clinician judgment).